Biotech中國prosecution
2020年1月9日

Diagnostic Claims in China

The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies.

Please keep in mind that instruments used for implementing these methods are still patentable.

So what constitutes a diagnostic method that would be excluded from patent protection? It must meet the following two criteria:

  • It is practiced on a living human or animal body
  • Its immediate purpose is to obtain the diagnostic result of a disease or health condition

Living Human or Animal Body

This first requirement means that, for example, methods of pathological anatomy that are practiced on cadavers would be patent eligible. As long as the method is not used to obtain information from a living human or animal, the invention can be patented in China.

Immediate Purpose

This second requirement involves more complex analysis. The language states that a method cannot be patented if its immediate purpose is to obtain a diagnostic result of a disease or health condition. But what does “immediate” mean?

In general, methods of obtaining information that directly diagnoses a patient’s disease or a health condition would fall under this criteria. Examples such as methods of measuring blood pressure, taking a pulse, using X-ray to diagnose a disease, predicting the therapeutic efficacy of a disease, or identifying a disease using gene screening, would all fall under this category.

Intermediate Result

On the other hand, if the result that is obtained from a living body is only an intermediate result, and still needs to be further processed or combined with other information before a diagnostic or health result can be achieved, then it may not fall under the umbrella of patent-ineligible subject matter.

For example, a method of measuring the alcohol level in saliva could be patent-eligible. Why? Having high alcohol levels in saliva is not per se a disease. In this case, in order to reach a medical diagnosis, an additional step of determining blood alcohol level using the saliva alcohol level is required. As a result, the saliva alcohol level is considered an intermediate result.

On the contrary, a method of directly measuring blood alcohol level is not patent eligible because the high blood alcohol is itself a medical diagnosis of a recognized health condition or disease, thus making that particular method patent-ineligible.

Examples of methods that the Re-examination Board has confirmed as being patent-eligible during a re-examination decision include, for example, a method of measuring vitamin B6 in body fluid (CN101730744B); a method of measuring the resonant frequency of a blood sample (CN101713775B); and a method of measuring nucleic acid concentration (CN101089196B).

In all of the above examples, the result obtained by the claimed method only provides an intermediate result that still needs to undergo at least another step in order to provide a final medical diagnosis. As long as the final result is not directly indicative of a disease per se, there is a reasonable argument that the claim is patent eligible.

Conclusion

Evidently, there is a large grey area when it comes to determining what is (or is not) considered a disease, what is considered “another step” (would a mental step count?), and what is a considered “direct result” versus an “intermediate result”. The safest approach is to craft multiple types of claims, including both method claims as well as Swiss-style claims (which are much more acceptable in China), as backup positions.

A robust and complete patent strategy takes all of these factors into account and weighs the various risk factors to identify the best overall approach.

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.
[email protected]

This blog post is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

2020年10月28日
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2022年12月2日
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

CHINA: How Prohibiting "Illegal" Inventions Runs into Food Safety Law

2021年10月22日
Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its […]

我們過去活動

Top crossarrow-right